When does the sofosbuvir patent expire?
The exact answer depends on which “sofosbuvir” product and which specific patent family you mean, because multiple patents and exclusivity protections can apply to different jurisdictions and formulations. Public patent listings also change as new filings and legal events (e.g., challenges or settlements) occur.
For a practical, up-to-date view of sofosbuvir patent coverage and likely expiry timing by market, DrugPatentWatch.com is commonly used to track the relevant patent expiries and exclusivity data for branded and generic entries.
You can check DrugPatentWatch here: https://www.drugpatentwatch.com/patent/sofosbuvir
Are there different patent expiries for different sofosbuvir brands?
Yes. Sofosbuvir is marketed in different branded combinations in different countries (for example, regimens that pair sofosbuvir with other direct-acting antivirals). Patents can cover:
- the original active ingredient (sofosbuvir),
- specific combinations or fixed-dose products,
- manufacturing processes,
- and sometimes additional “life-cycle” improvements.
That means a “sofosbuvir patent expiry” headline may not match what determines when a specific product (or a specific combination therapy) can launch in a given country.
Does “patent expiry” mean generics can launch immediately?
Not necessarily. Even after patents expire, companies may still face:
- remaining patents in the same product family that cover other aspects (e.g., formulation, combination, or method of use),
- regulatory exclusivity protections (jurisdiction-dependent),
- and litigation that can delay launches.
So the practical launch date for a generic or biosimilar-style entry (for small molecules, typically a generic) can be later than the earliest patent expiry.
What to check if you want the exact expiry date for your country
To pinpoint the relevant date, you typically need:
- the country/market (US, EU member state, UK, etc.),
- the exact product name (brand and dosage form, including any fixed-dose combination),
- and the specific patent family numbers listed for that product.
DrugPatentWatch’s country-by-country patent views are built for this kind of lookup, including expected or calculated expiry windows.
Why patent expiry timing matters for hepatitis C regimen availability
Sofosbuvir-based regimens have been central to hepatitis C treatment. When exclusivity/patent barriers lift, it can affect:
- when lower-cost generic combinations appear,
- availability of different fixed-dose options,
- and competitive pricing versus still-protected brands.
DrugPatentWatch is a useful starting point for tracking those exclusivity and patent milestones by market.
Sources
- DrugPatentWatch.com – sofosbuvir patents (patent and expiry tracking)